膜性肾病生物标志物的研究现状与应用展望

doi:10.3969/j.issn.1673-8640.2023.12.001

摘要/Abstract

摘要：

膜性肾病（MN）是成人肾病综合征中最常见的病理类型，是成人终末期肾病的重要病因之一。MN的病程具有异质性，有1/3的患者会自发缓解或病情稳定，有1/3的患者病情则会持续进展，如未能及时诊断和规范治疗，将发展为终末期肾病。因此，早期发现预后不良患者，及时规范治疗和定期随访，具有重要的临床意义。肾活检是诊断MN的金标准。近年来，抗M型磷脂酶A2受体（PLA2R）抗体的临床应用极大地推动了MN的诊疗。最新的MN诊疗指南明确提出，在排除继发性MN后，符合MN临床表现和血清抗PLA2R抗体阳性患者不需要再进行肾活检来明确诊断。随着相关研究的不断深入，1型血小板反应蛋白7A域（THSD7A）等一系列新的MN潜在标志物被发现，对抗PLA2R抗体阴性MN的辅助诊断有较高的临床价值。因此，加强MN新型生物标志物的临床应用研究，综合运用相关生物标志物，将有助于推进MN的精准诊疗。

关键词: M型磷脂酶A2受体, 自身抗体, 膜性肾病

Abstract:

Membranous nephropathy（MN） is the most common pathological type of adult nephrotic syndrome and a significant contributor to adult end-stage renal disease. The course of MN varies，with 1/3 patients experiencing spontaneous remission or stable disease，while 1/3 patients continue to progress. Without timely diagnosis and standardized treatment，MN can lead to end-stage renal disease. Therefore，early determination of patients with poor prognosis，timely standardized treatment and regular follow-up are crucial. Renal biopsy is the gold standard for diagnosing MN. Recently，the clinical application of anti-M-type phospholipase A2 receptor（PLA2R） antibody determination has improved the diagnosis and treatment of MN. According to the latest MN diagnosis and treatment guidelines，it is now clear that renal biopsy is not necessary to confirm the diagnosis of MN after ruling out secondary MN. With research progress，several new potential markers for MN，including thrombospondin type1 domain-containing 7A（THSD7A），have been discovered. These markers are valuable for assisting in the diagnosis of anti-PLA2R antibody-negative MN. Therefore，it is important to conduct further clinical research on these new MN biomarkers and utilize a comprehensive approach to their application in order to enhance the accuracy of MN diagnosis and treatment.

Key words: M-type phospholipase A2 receptor, Autoantibody, Membranous nephropathy

中图分类号:

R446.1

范列英. 膜性肾病生物标志物的研究现状与应用展望[J]. 检验医学, 2023, 38(12): 1111-1114.

FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy[J]. Laboratory Medicine, 2023, 38(12): 1111-1114.

参考文献 22

[1]	COUSER W G. Primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(6):983-997. DOI URL
[2]	PAN X, XU J, REN H, et al. Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years:a single-center study in China[J]. Contrib Nephrol, 2013, 181(181):22-30.
[3]	RADHAKRISHNAN J, CATTRAN D C. The KDIGO practice guideline on glomerulonephritis:reading between the(guide)lines-application to the individual patient[J]. Kidney Int, 2012, 82(8):840-856. DOI URL
[4]	BECK L H Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. DOI URL
[5]	Kidney Disease:Improving Global Outcomes(KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S):S1-S276. DOI PMID
[6]	陈瑞颖, 鲁鉴达, 谢琼虹, 等. 成人磷脂酶A2受体相关特发性膜性肾病的自然病程和治疗反应的影响因素[J]. 中华肾脏病杂志, 2019, 35(1):1-8. DOI
[7]	KAGA H, KOMATSUDA A, YAMAMOTO S, et al. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA[J]. Clin Exp Nephrol, 2019, 23(4):465-473. DOI PMID
[8]	TOMAS N M, BECK L H Jr, MEYER-SCHWESINGER C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J]. N Engl J Med, 2014, 371(24):2277-2287. DOI URL
[9]	HOXHA E, WIECH T, STAHL P R, et al. A mechanism for cancer-associated membranous nephropathy[J]. N Engl J Med, 2016, 374(20):1995-1996. DOI URL
[10]	HOXHA E, BECK LH Jr, WIECH T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(2):520-531. DOI PMID
[11]	SETHI S, DEBIEC H, MADDEN B, et al. Neural epidermal growth factor-like 1 protein(NELL-1) associated membranous nephropathy[J]. Kidney Int, 2020, 97(1):163-174. DOI URL
[12]	CAZA T N, HASSEN S I, DVANAJSCAK Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy[J]. Kidney Int, 2021, 99(4):967-976. DOI URL
[13]	WANG G, SUN L, DONG H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients[J]. Clin J Am Soc Nephrol, 2021, 16(5):727-735. DOI URL
[14]	SETHI S, DEBIEC H, MADDEN B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients[J]. Kidney Int, 2020, 98(5):1253-1264. DOI PMID
[15]	SETHI S, MADDEN B, DEBIEC H, et al. Protocadherin 7-associated membranous nephropathy[J]. J Am Soc Nephrol, 2021, 32(5):1249-1261. DOI PMID
[16]	SETHI S, MADDEN B J, DEBIEC H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy[J]. J Am Soc Nephrol, 2019, 30(6):1123-1136. DOI PMID
[17]	IWAKURA T, EMA C, ISOBE S, et al. Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy:a single-center retrospective study in Japan[J]. Sci Rep, 2022, 12(1):2967. DOI
[18]	AL-RABADI L F, CAZA T, TRIVIN-AVILLACH C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy[J]. J Am Soc Nephrol, 2021, 32(7):1666-1681. DOI URL
[19]	LI Q, XU M, ZHANG Z, et al. Urinary exosomal hsa_circ_0001250 as a novel diagnostic biomarker of idiopathic membranous nephropathy[J]. J Transl Med, 2022, 20(1):607. DOI PMID
[20]	ZHOU G, JIANG N, ZHANG W, et al. Biomarker identification in membranous nephropathy using a long non-coding RNA-mediated competitive endogenous RNA network[J]. Interdiscip Sci, 2021, 13(4):615-623. DOI PMID
[21]	DUAN S, CHEN S, LU F, et al. Serum 25-hydroxyvitamin D as a predictive biomarker of clinical outcomes in patients with primary membranous nephropathy[J]. Front Nutr, 2023, 10:1171216.
[22]	李臻, 李贞, 陈伟琴, 等. 血浆纤溶标志物在原发性膜性肾病疾病进展中的变化[J]. 检验医学, 2020, 35(1):25-28.